Dr. Lu Zhou obtained his B.S. and Ph.D. degree from Peking University (China) in 2001 and 2006. He accepted an assistant professorship position at Fudan University in 2008 and was promoted to associate professor in 2013. During that time, he did his postdoctoral training at the University of Chicago (USA) in 2010. He became involved in medicinal chemistry and chemical biology. Now, he focused on cancer metabolism pathway and developed small molecule inhibitors against key enzymes in glycolytic pathway to understand metabolic flux in cancer cells. The aim of his research is to find potential drug targets and candidates for cancer chemotherapy. He has published more than 30 scientific publications, including many peer reviewed journal articles such as Nature Chemistry, Cancer Cell and Nature Communications.
Medicinal Chemistry; Chemical Biology; Cancer Metabolism; Structural Biology
Education
1997-2001 B.S. Chemistry, Peking University
2001-2006 Ph.D. Physical Chemistry, Peking University
Employment History
2006-2008 Postdoctoral Fellow, Department of Chemistry, Peking University
2008-2019 Assistant Professor, School of Pharmacy, Fudan University
2010-2012 Visiting Assistant Professor, Department of Chemistry, Universitiy of Chicago
2019.12- Professor, School of Pharmacy, Fudan University
Honors and Awards
2015 Shanghai Rising-Star Program, Shanghai Science and Technology Committee
2010 Research Grant Awards for the Youth, National Science Foundation
2007 Postdoctoral Fellowship, China Postdoctoral Science Foundation
Research Funding
National Science Foundation China, 2010 (3 years)
National Science Foundation Shanghai, 2013 (3 years)
National Science Foundation China, 2015 (4 years)
Shanghai Rising-Star Program, 2015 (3 years)
National Science Foundation China, 2018 (4 years)
Courses Taught
Undergraduate: "Chemical biology", "Drug design", "Organic synthesis experiment"
Graduate: "Advanced medicinal chemistry", "Biomacromolecules and biopharmaceuticals"
Publications
1. Yang X#, Shen J#, Jiang L#, Li W, Yu M, Pan G，Yan Y, Zhang C, Jia W, Xiao L, Yu H, Chen H, Zheng Y, Yu L, Xie Q*, Zhou L*, Shao L*, Discovery, cocrystallization, molecular-docking and biological evaluation of novel high affinity Ls-AChBP ligands possessing α7 nAChR partial agonist/antagonist activities. Eur. J. Med. Chem. 2018, in press.
2. Mo M, Yang J, Jiang XC, Cao Y, Fei J, Chen Y, Qi X, Chu Y, Zhou L*, Ye D*. Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice. J. Med. Chem. 2018; 61(18):8241-8254.
3. Wang P, Jiang L, Cao Y, Ye D*, Zhou L*. The Design and Synthesis of N-Xanthone Benzenesulfonamides as Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors. Molecules. 2018; 23(6). pii: E1396.
4. Wang P, Jiang L, Cao Y, Zhang X, Chen B, Zhang S, Huang K, Ye D*, Zhou L*. Xanthone derivatives as phosphoglycerate mutase 1 inhibitors: Design, synthesis, and biological evaluation. Bioorg. Med. Chem. 2018; 26(8):1961-1970.
5. Liu SE, Hu JC, Zhang H, Xu P, Wan W, Zheng MY, Yu KQ, Ding H, Jiang HL, Zhou L*, Luo C*. Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1. Acta Pharmacol Sin. 2017 Jul 27.
6. Shen J, Yang XC, Yu MC, Xiao L, Zhang XJ, Sun HJ, Chen H, Pan GX, Yan YR, Wang SC, Li W*, Zhou L*, Xie Q, Yu LQ, Wang YH, Shao LM*. Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands. Acta Pharmacol Sin. 2017;38(1):146-155.
7. Zhou P#, Liu Y#, Zhou L#, Zhu K, Feng K, Zhang H, Liang Y, Jiang H, Luo C*, Liu M*, Wang Y*. Potent Antitumor Activities and Structure Basis of the Chiral β-Lactam Bridged Analogue of Combretastatin A-4 Binding to Tubulin. J Med Chem. 2016 ;59(22):10329-10334.
8. Song J, Peng P, Chang J, Liu MM, Yu JM, Zhou L*, Sun X*. Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis. Bioorg Med Chem Lett. 2016; 26(9):2174-8.
9. Zhong D, Liu M, Cao Y, Zhu Y, Bian S, Zhou J, Wu F, Ryu KC, Zhou L*, Ye D*. Discovery of Metal Ions Chelator Quercetin Derivatives with Potent Anti-HCV Activities. Molecules. 2015;20(4):6978-99.
10. Zhou L#, Bosscher M#, Zhang C#, Oz?ubuk?u S, Zhang L, Zhang W, Li CJ, Liu J, Jensen MP, Lai L*, He C*. A protein engineered to bind uranyl selectively and with femtomolar affinity. Nat Chem. 2014;6(3):236-41.
11. Hitosugi T#, Zhou L#, Fan J, Elf S, Zhang L, Xie J, Wang Y, Gu TL, Ale?kovi? M, LeRoy G, Kang Y, Kang HB, Seo JH, Shan C, Jin P, Gong W, Lonial S, Arellano ML, Khoury HJ, Chen GZ, Shin DM, Khuri FR, Boggon TJ, Kang S, He C, Chen J. Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun. 2013;4:1790. (#contribute equally)
12. Song WH, Liu MM, Zhong DW, Zhu YL, Bosscher M, Zhou L*, Ye DY*, Yuan ZH*. Tetrazole and triazole as bioisosteres of carboxylic acid: discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents. Bioorg Med Chem Lett. 2013;23(16):4528-31.
13. Hitosugi T#, Zhou L#, Elf S, Fan J, Kang HB, Seo JH, Shan C, Dai Q, Zhang L, Xie J, Gu TL, Jin P, Ale?kovi? M, LeRoy G, Kang Y, Sudderth JA, DeBerardinis RJ, Luan CH, Chen GZ, Muller S, Shin DM, Owonikoko TK, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Ye K, Boggon TJ, Kang S, He C, Chen J. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 2012;22(5):585-600. (#contribute equally)
